Ovarian Cancer Treatment Drugs Market - By Cancer Type (Epithelial, Stromal, Germ Cell), By Treatment Type (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration (Oral, Intravenous), By End-user & Forecast, 2024 - 2032

Some of the top ovarian cancer treatment drugs industry players are F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Astrazeneca, Merck KGaA, Oasmia Pharmaceutical AB, Clovis Oncology, Inc., Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Allarity Therapeutics, among others.

Industry size for ovarian cancer treatment drugs reached USD 3.5 billion in 2023 and is projected to be worth USD 6.1 billion by 2032 driven by the high incidence of ovarian cancer globally.

The targeted therapy drugs segment accounted for 43.7% revenue share of the ovarian cancer treatment drugs industry in 2023 and is projected to record substantial growth through 2032 owing to the benefits identifying and combating cancer cells precisely and minimizing harm to healthy cells.

North America industry for ovarian cancer treatment drugs held a sizable revenue share in 2023 and is projected to record robust growth through 2032 attributed to the growing number of patients with ovarian cancer across the region.